Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase
Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.